Optimal Management of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations

Author： Lin Chia-Chi Yang James Chih-Hsin

ISSN： 0012-6667

Source： Drugs, Vol.71, Iss.1, 2011-01, pp. : 79-88

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Serum Detection of Epidermal Growth Factor Receptor Gene Mutations Using Mutant-enriched Sequencing in Chinese Patients with Advanced Non-small Cell Lung Cancer

By Jiang B Liu F Yang L Zhang W Yuan H Wang J Huang G

The Journal of International Medical Research, Vol. 39, Iss. 4, 2011-07 ,pp. : 1392-1401

Field House Publishing

Access to resources Recommend Favorite

Gefitinib is an effective treatment for patients with non-small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer

By Dancey Janet E.

Drugs, Vol. 67, Iss. 8, 2007-01 ,pp. : 1125-1138

Adis International

Access to resources Recommend Favorite

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3896-3901

Blackwell Publishing

Access to resources Recommend Favorite

Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer

By Agelaki Sofia Georgoulias Vassilis

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 4, 2005-11 ,pp. : 855-874

Informa Healthcare

Access to resources Recommend Favorite